

Press Release



Magellan BioScience Group, Inc.
6101 Johns Road, Suite 8,
Tampa, FL 33634 USA
Tel (727) 865-1300
Fax (813) 514-9401
<http://www.magellanbioscience.com>

FOR IMMEDIATE RELEASE: 06 October 2008

Tampa, FL

Magellan BioScience Group, Inc. is pleased to announce the appointment of Dr. Ian Cottrell as their Vice President of Business Development

Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug discovery and development from marine microbial sources announced today the appointment of Dr. Ian Cottrell as their new Vice President of Business Development.

An industry veteran, Cottrell is an experienced executive with extensive business and technology expertise in pharmaceuticals, specialty chemicals, cosmetics and animal health consumer products. He has held senior executive positions such as Vice President of Chemical Product Development at The Hartz Mountain Corporation, Global Director of Personal Care Technology at Unilever, and Director of Technology at Rhône-Poulenc S.A.. He began his career in 1970 as a research chemist for Stein, Hall & Co, (a Celanese Corporation).

Dr. Cottrell currently has fifty six patents with the United States Patent and Trademark Office and more than 26 publications in peer-reviewed journals. He has been involved in all aspects of product lifecycles from new product development through business and technology management including discovery, regulatory, and manufacturing

"Ian brings a wealth of experience and leadership to Magellan. He understands the tremendous potential of the ever-expanding libraries at Magellan's disposal and, brings a breadth of knowledge for the potential outside of the arenas where we are already well-established such as specialty chemicals," stated Todd R. Daviau, President and CEO.

Dr. Cottrell's unique background in consumer and specialty chemicals compliments Magellan's already diverse offerings to its clients in the pharmaceutical and agrochemical markets. It expands the company's team structure and ability to become a direct extension of our clients internal new product discovery divisions.

"Ian's knowledge strengthens Magellan's potential for additional discovery services," said Dr. John M. Cronan, Vice President. "We look forward to his insights and leadership."

About Magellan:

Magellan BioScience Group, Inc., based in Tampa, Fla., is a privately held innovative biotechnology company focused on the discovery of novel classes of therapeutic candidates. Magellan is using its integrated platform technologies to isolate and identify new biologically active compounds. The company believes that its library of marine microbes will be the next source of drug discovery for the pharmaceutical industry. Magellan aims to develop and optimize drug candidates to treat cancer, infectious diseases, and inflammation. For additional information, please refer to the company's web site at www.magellanbioscience.com.

CONTACTS:

Todd R. Daviau, Ph.D.,

Magellan BioScience Group, Inc.

6101 Johns Road, Suite 8

Tampa, FL 33634 USA

Phone: (727) 865-1300

Fax: (813) 514-9401

Email: info@magellanbioscience.com

<http://www.magellanbioscience.com>